IQVIA Holdings, Inc. Common Stock (IQV)

Clinical research company IQVIA (NYSE: IQV) announced better-than-expected revenue in Q2 CY2025, with sales up 5.3% year on year to $4.02 billion. The company’s full-year revenue guidance of $16.2 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $2.81 per share was 1.4% above analysts’ consensus estimates.

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

It was a quiet Tuesday on Wall Street, as major indexes edged lower with investors pausing ahead of a critical wave of tech earnings.

Shares of clinical research company IQVIA (NYSE: IQV) jumped 15.9% in the morning session after the company reported second-quarter financial results that beat Wall Street expectations and raised its full-year profit guidance. 

Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Iqvia stock surged Tuesday after the clinical resource organization widely beat most second-quarter metrics.

Clinical research company IQVIA (NYSE: IQV) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 5.3% year on year to $4.02 billion. The company’s full-year revenue guidance of $16.2 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $2.81 per share was 1.4% above analysts’ consensus estimates.

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Clinical research company IQVIA (NYSE: IQV) will be reporting earnings this Tuesday before the bell. Here’s what you need to know.

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 3.5%. This performance was disheartening since the S&P 500 gained 4.5%.

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest of the drug development inputs & services stocks fared in Q1.

Nvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical workflows.

IQVIA stock may look ready for a breakout, but Adhishthana analysis reveals a complex time spiral that could last until 2030.

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.